Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the company's $1 trillion valuation. Investors watch weight loss effectiveness, side effects, and patient dropout rates closely, as these factors impact long-term revenue. A strong result could solidify Eli Lilly's lead in obesity treatments, while weaker data might expose valuation risks amid pricing pressures and competition.
Eli Lilly's stock price on Pluang is currently USD 1,152.95 with a slight 1-day increase of 0.07%, supporting its $1.03 trillion market cap. The company's shares have a typical hold time of 92 days, reflecting steady investor interest. These figures are as of Sep 19, 2026, 04:31 WIB.
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven mainly by volume growth from key drugs like Mounjaro and Zepbound, with earnings per share beating estimates. Despite a bullish pipeline and raised revenue guidance, the company faces cha...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with...
The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benc...
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...
